CASI Pharmeceuticals

EVOMELA®

EVOMELA

13 March 2019

CASI Pharmaceuticals Announces Exclusive Distribution Partner For Melphalan Hydrochloride For Injection (EVOMELA®) In China

3 December 2018

CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (Trademark: EVOMELA®)


EVOMELA® (melphalan) for Injection is a new intravenous formulation of melphalan being investigated by our licensor in the multiple myeloma transplant setting. The formulation avoids the use of propylene glycol, which is used as a co-solvent in the current formulation of melphalan and has been reported to cause renal and cardiac side-effects that limit the ability to deliver higher quantities of intended therapeutic compounds. The use of Captisol technology to reformulate melphalan is anticipated to allow for longer administration durations and slower infusion rates, potentially enabling clinicians to avoid reductions and safely achieve a higher dose intensity of pre-transplant chemotherapy. Spectrum Pharmaceuticals received FDA NDA approval in March 2016. We will submit import drug registration application for EVOMELA in greater China.

About Us

CASI is a U.S. NASDAQ-listed pharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China through which substantially all of our operations are conducted.

Learn More

Presentation

Corporate Presentation - BIO CEO & Investor Conference

Download →

Presentation

Annual Meeting Presentation

Download →